MELISSA – Mobile Artificial Intelligence Solution for Diabetes Adaptive Care

The use of AI enabled personalized devices to manage health is a rapidly growing industry. The ethical concerns and challenges accompanying this trend is an important question to confront as these tools are being developed and forms of governance are being considered.

The number of people being diagnosed with diabetes is growing across the globe, with the WHO estimating that it was the ninth leading cause of death worldwide in 2019. Diabetes management and treatment is, thus, an increasingly important issue for healthcare systems worldwide. This EU Horizons funded project’s main objective is to provide a clinically validated, efficient and cost-effective AI-based digital diabetes management solution, providing personalized treatment and care recommendations.

As part of the consortium, the TUM IEAI will investigate the ethical aspects related to trustworthy AI to provide user requirements and recommendations to the development teams.

News & Updates

Principal Investigators


Prof. Dr. Christoph Lütge

Prof. Dr. Christoph Lütge, TUM School of Social Sciences and Technology, Institute for Ethics in AI


  • Alexander Kriebitz, Institute for Ethics in AI
  • Raphael Max, Institute for Ethics in AI
  • Lameck Amugongo, Institute for Ethics in AI